Harley-Davidson, Inc.
Harley-Davidson, Inc. (NYSE: HOG) is a global leader in heavyweight motorcycles, apparel, parts, and accessories. It sells custom, cruiser, and touring motorcycles and Harley-Davidson parts, accessories, riding gear, clothes, and retail.
Key Highlights
- The company reported a 39.10% rise in motorcycles and related products revenue to USD 4.54 billion in FY21 (ended December 31, 2021) compared to USD 3.26 billion in FY20.
- The company reported a sharp uptick in the bottom line to USD 650.02 million in FY21 from USD 1.30 million in FY20.
- EBITDA and net margins were 15.5% and 12.2%, respectively, higher than the industry median of 8.1% and 5.4%.
- On the other hand, HOG's cash conversion cycle is unusually long, at 175.6 days in FY21, against the industry median of 35.6 days. As of FY21, it has a debt-to-equity ratio of 2.70x, indicating a higher risk to lenders and investors.
- Stock is currently trading above its crucial long-term as well as short-term 50-day and 200-day SMA support levels.
- Stock is currently leaning towards the mid-band of the 52-week range of USD 32.13 to USD 52.06.
- Over the last week and month, HOG's stock price has climbed 15.85% and 8.47%, respectively.
Three-Year Technical Price Chart (as of February 11, 2022; at 3:01 PM ET). Analysis by Kalkine Group
Conclusion: Considering the company's robust growth prospects, solid margins, higher debt, global chip shortage, and other technical indicators, we recommend a "Watch" rating on the stock at the current price of USD 41.43, down 2.70% as of February 11, 2022, at 3:01 PM ET.
*The reference data in this report has been partly sourced from REFINITIV.
Hepion Pharmaceuticals, Inc.
Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA) is a biopharmaceutical firm specializing in developing pharmacological therapy for chronic liver illnesses. CRV431, a cyclophilin inhibitor, is being developed by the company to help treat these numerous complicated diseases.
Key Highlights:
- The company has not yet commenced its core commercial operations.
- Net loss for Q3FY21 increased to USD 9.27 million from USD 6.24 million reported in Q3FY20, attributable to high operating expenditure.
- On January 26, 2022, HEPA revealed the favorable results of a nonclinical research study indicating that when rencofilstat (CRV431) was paired with an anti-PD1 antibody, an immune checkpoint inhibitor (ICI), it synergistically suppressed liver tumor development and extended mice survival.
- The stock is currently trading below its critical short-term (50-day) and long-term (200-day) DMA support levels, indicating a bearish trend.
- It is leaning towards the lower-band of the 52-week range of USD 0.86 to USD 3.18.
- The stock price has fallen 35.85% and 64.08% in the past nine and twelve months.
Three-Year Technical Price Chart (as of February 11, 2022; 3:05 PM ET). Analysis by Kalkine Group
Conclusion: Considering the company's significant losses, positive results from clinical studies, anticipated growth, and other technical indicators, we recommend a "Watch" rating on the stock at the current price of USD 1.02, down 4.67% as of February 11, 2022, at 3:05 PM ET.
*The reference data in this report has been partly sourced from REFINITIV.
Disclaimer - This report has been issued by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and prepared by Kalkine and its related bodies corporate authorised to provide general financial product advice. Kalkine.com.au and associated pages are published by Kalkine.
Any advice provided in this report is general advice only and does not take into account your objectives, financial situation or needs. You should therefore consider whether the advice is appropriate to your objectives, financial situation and needs before acting upon it.
There may be a Product Disclosure Statement, Information Statement or other offer document for the securities or other financial products referred to in Kalkine reports. You should obtain a copy of the relevant Product Disclosure Statement, Information Statement or offer document and consider the statement or document before making any decision about whether to acquire the security or product.
You should also seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) as necessary before acting on any advice in this report or on the Kalkine website. Not all investments are appropriate for all people.
The information in this report and on the Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of information contained in its reports, newsletters and websites. All information represents our views at the date of publication and may change without notice.
Kalkine does not guarantee the performance of, or returns on, any investment. To the extent permitted by law, Kalkine excludes all liability for any loss or damage arising from the use of this report, the Kalkine website and any information published on the Kalkine website (including any indirect or consequential loss, any data loss or data corruption). If the law prohibits this exclusion, Kalkine hereby limits its liability, to the extent permitted by law, to the resupply of services.
Please also read our Terms & Conditions and Financial Services Guide for further information.
On the date of publishing this report (referred to on the Kalkine website), employees and/or associates of Kalkine and its related entities do not hold interests in any of the securities or other financial products covered on the Kalkine website unless those persons comply with certain safeguards, procedures, and disclosures.
Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.